Supernus Pharmaceuticals | SUPN - Cash And Equivalent


Supernus Pharmaceuticals reported $184.87M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
ANI Pharmaceuticals USD 311.18M 25.59M Mar/2026
Aurora Cannabis CAD 56.36M 39.33M Dec/2025
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Canopy Growth CAD 371.32M 73.26M Dec/2025
Cara Therapeutics USD 20.73M 684K Dec/2025
Corcept Therapeutics USD 108.74M 11.76M Mar/2026
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 144.31M 14.24M Mar/2026
Perrigo USD 531.6M 99.5M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
Supernus Pharmaceuticals USD 184.87M 56.42M Mar/2026
United Therapeutics USD 1.28B 277.4M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026